Interdigitating Dendritic Cell Sarcoma of the Eyelid With a Rapidly Fatal Course

I
nterdigitating dendritic cells participate in the immune system as antigen-presenting cells, stimulating T lymphocytes. Interdigitating dendritic cells normally are localized in the T-cell-rich areas of lymph nodes and are believed to be derived from hematopoietic precursors and to belong to the mononuclear phagocytic system. Interdigitating dendritic cells sarcoma is an extremely rare malignancy derived from these antigen-presenting cells normally localized in lymphoid organs. Only 45 cases have been reported in the literature to date. 1, 2 We are unaware of previous reports of this sarcoma in the eyelid and could not find any reference to it in a MEDLINE search.
Report of a Case.
A 72-year-old man who had an unknown recurrent lesion in his lower right eyelid for 8 months was referred to our department. Two prior biopsies revealed a nevoid lesion and dermatofibroma. The patient was referred to our clinic when the tumor recurred. His best-corrected visual acuity was 0.8 OD. A 20-mm ϫ 6-mm multinodular, ulcerated tumor was present on his right lower eyelid (Figure 1) . The anterior chamber and the vitreous were free of inflammation and the lens revealed a mild senile cataract. The patient underwent sufficient surgical resection with a 4-mm-wide tumor-free margin and reconstruction using a tarsoconjunctival flap combined with a skin graft. Microscopically, the tumor consisted of medium to large spindle-shaped cells with hyperchromatic nuclei. The cells were arranged in fascicles and formed whorls. The mitotic count was high (Figure 2) . The final diagnosis was interdigitating dendritic cell sarcoma. The tumor cells strongly expressed S-100 protein, and many tumor cells showed reactivity with antibodies to lysozyme and CD68 as well as CD45 (Figure 3) . Numerous small, reactive CD3-positive T lymphocytes were mixed. Some tumor cells were positive for CD83 and fascin. No reactivity was seen with antibodies to cytokeratins, HMB-45, Melan-A, or CD1a or as markers for follicular dendritic cells, such as CD21, CD23, and CD35. The tumor staging revealed no metastatic disease. After careful deliberation of treatment options with his oncologist, the patient declined chemotherapy and local radiation therapy. Two years later, the patient had a local recurrence and metastatic lung and liver disease. A biopsy of a presumed metastasis in the lung confirmed the diagnosis. His clinical condition deteriorated and he died rapidly.
Comment. Interdigitating dendritic cell sarcoma is an extremely rare malignancy derived from antigenpresenting cells. Monocytes and related cells can be divided into 2 major categories: phagocytes and dendritic cells. The dendritic cells include (1) the follicular dendritic cell, (2) the Langerhans cell, (3) the intestinal dendritic cell, (4) the indeterminate cell, and (5) the interdigitating dendritic cell. Special immunohistochemical markers help to classify these dendritic cell neoplasms. The immunohistochemical diagnosis in this case was based on the World Health Organization classification for hematopoietic and lymphoid tissues. 3 Patients with interdigitating dendritic cell sarcoma usually have lymphnode enlargement at initial examination, though they rarely have extranodal disease. A solitary skin tumor similar to our patient's was reported by Miracco et al. 4 This sarcoma has a high potential of local recurrence and systemic disease. Of only 45 cases that have been reported in the world literature, the median overall survival (Kaplan-Meier method) from the time of diagnosis is reported to be 15 months. 5 There is no consensus on a standard chemotherapy or radiation therapy regimen for interdigitating dendritic cell sarcoma. Chemotherapy regimens used in malignant lymphoma showed variable degrees of remission; field radiation seems to be the best treatment of localized disease. 6 To our knowledge, interdigitating dendritic cell sarcoma has not involved the eyelid. Although optimal therapy for this tumor is yet to be determined, adjuvant chemotherapy or radiation therapy may be reasonable given its highly malignant course.
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A B Figure 3 . Immunohistochemical investigation showed that the tumor cells strongly expressed S-100 protein (left side) and many tumor cells were positive for CD68 (right side) (stained using the streptavidin-biotin complex method; original magnification ϫ400). 2 could lead to mismanagement and inappropriate care for infants with retinopathy of prematurity (ROP). Based on their study, Chiang and colleagues concluded: "Interexpert agreement of plus disease diagnosis is imperfect. This may have important implications for clinical ROP management, continued refinement of the international ROP classification system, development of computer-based diagnostic algorithms, and implementation of ROP telemedicine systems." 1(p875) These comments imply more than the words stipulate. We believe that many readers will interpret this conclusion to mean that the diagnosis of plus disease is so faulty that it is useless in the management of ROP.
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The conclusions drawn by Chiang et al are inappropriate for the design of their study. Selected wide-angle photographs were sent to experts for their review. Noticing considerable disagreement in the diagnosis of plus disease among these experts, Chiang et al made far-reaching conclusions about the inability of experts to agree on the proper diagnosis of plus disease. Such a conclusion would require masked paired examinations of the same infant rather than a review of wide-angle photographs.
Additional flaws in the study design are apparent. The camera used in the experiment offers a minified view compared with the standard reference photograph of plus disease. 3 The camera itself places weight on the eye and can change the appearance of plus disease or stage 3 ROP. Experts were shown photos that were devoid of any other anatomical information (eg, presence or absence of stage 3 disease). These additional factors are helpful during indirect ophthalmoscopy in real life. Pictures shown to experts were very ambiguous. Thus, Chiang et al probed interexpert agreement in a gray area, exactly where disagreement is expected.
Given the design of the study, the only appropriate conclusion is that the use of wide-angle photographs leads to considerable variability in the assessment of plus disease. This study calls into question the use of the wideangle photographs for the diagnosis of plus disease, rather than the diagnosis of plus disease per se.
If readers interpret these articles to indicate that plus disease is an unreliable feature of ROP diagnosis, then their clinical practice behavior may change in a dangerous way. Indeed, it is hard to imagine any resulting change in practice that would benefit the collective group of infants who have advanced ROP. Plus disease is difficult to diagnose clinically in borderline cases; however, when the full spectrum of plus disease is considered, there are few characteristics of ROP that have demonstrated such a strong association with the clinical sequelae of ROP. A change in practice that leaves out plus disease or causes physicians to underestimate its importance, based on this study, could place many children at increased risk of blindness.
We urge clinicians to continue to emphasize the importance of plus disease in clinical decision making. Plus disease has been extensively and clinically tested as one of the most important and alarming findings in ROP. Meanwhile, Chiang and colleagues have shown us that wide-angle photography is not useful for the diagnosis of plus disease. For this observation, we can be grateful.
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